FDA approves 1st rapid-acting insulin
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus.
NSYNC’s Lance Bass shares his journey with type 1.5 diabetes, also known as latent autoimmune diabetes in adults (LADA). The ...
People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With ...
Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...
Ketone supplements are emerging as a potential game-changer in the fight against type 2 diabetes, a global health crisis ...
Cross-industry collaboration is key to fighting rising costs for consumers. The Fast Company Impact Council is a private ...
Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.
Mother, Kerrie Struhs, 49, brother, Zachary Struhs, and the 10 others were convicted on grounds they counseled or encouraged Jason Struhs to withdraw insulin therapy. However, Justice Burns ...
Surrogate measures of insulin resistance, based on the triglyceride-glucose index, can be used to predict the development of ...
People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies, insulin administration is manually controlled, while hybrid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback